Drug Profile


Alternative Names: CLS-003; Furosemide/digoxin; ICVT; Ionic contra viral therapy

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Henderson Morley
  • Developer Cutanea Life Sciences; Henderson Morley
  • Class Antihypertensives; Antivirals; Glycosides; Skin disorder therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Potassium channel antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Genital warts; Vulvar intraepithelial neoplasia; Warts
  • Discontinued Herpes simplex virus infections; Human papillomavirus infections; Infectious keratoconjunctivitis

Most Recent Events

  • 01 Dec 2017 Chemical structure information added
  • 05 Oct 2017 Phase-II clinical trials in Vulvar intraepithelial neoplasia in Netherlands (Topical) (NCT03334240)
  • 05 Oct 2017 Cutanea Life Sciences initiates enrolment in a phase II trial for Genital warts in Netherlands (Topical) (NCT03334240)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top